Vor Biopharma Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
VOR$19.56-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year EndedDecember 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2025 | 2024 |
| Operating expenses: | ||
| Research and development | $321,532 | $93,310 |
| General and administrative | 50,110 | 27,875 |
| Total operating expenses | $371,642 | $121,185 |
| Loss from operations | $(371,642) | $(121,185) |
| Other income (expense), net: | ||
| Interest income | 5,868 | 4,271 |
| Other income | 4,151 | — |
| Change in fair value of warrant liabilities | (334,358) | — |
| Total other income (expense), net | (324,339) | 4,271 |
| Net loss | $(695,981) | $(116,914) |
| Net loss per share, basic and diluted | $(70.50) | $(34.03) |
| Weighted-average common shares outstanding, basic and diluted | 9,871,866 | 3,435,533 |
| Other comprehensive income: | ||
| Unrealized gain on available for sale marketable securities | 19 | 99 |
| Total other comprehensive income | 19 | 99 |
| Comprehensive loss | $(695,962) | $(116,815) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.